What Have We Learned From the Idiopathic Intracranial Hypertension Treatment Trial the William F. Hoyt Lecture.

Acetazolamide significantly improved papilledema grade and OCT optic disc volume and reduced cerebrospinal fluid pressure by an additional 60-mm H2O compared with placebo (P = 0.002).

Seven participants experienced treatment failure (6 placebo, 1 acetazolamide).

Risk factors for treatment failure were high-grade papilledema, more than 30 transient visual obscurations per month, visual acuity loss, and male sex.

Compliance of study drug was high (89% vs 93%).